Recent Updates
Recently added Catalysts
BMRN Positive Sentiment

BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET

Key Takeaway: BioMarin Pharmaceutical Inc. will host a conference call on November 2, 2026, at 4:30 p.m. ET. CEO Alexander Hardy will discuss the company's third quarter 2026 financial results and provide a business update. Interested parties can access the call via the investor section of BioMarin's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • BioMarin is hosting a conference call to discuss financial results.
  • The company has a strong clinical and preclinical pipeline.
  • BioMarin has a proven track record of innovation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+14%
120-day peak, hindsight
Typical move
6.4%
average across 10 past catalysts
Lead asset
N-acetylgalactosamine 4-sulfatase
Phase 3 · Mucopolysaccharidosis VI

Full Press Release Details

SAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, November 2, 2026, at 4:30 p.m. ET to discuss third quarter 2026 financial results and provide a general business update.

Dial-in Number U.S. / Canada Dial-in Number: +1 833-461-5787 International Dial-in Number: +1 626-884-3620 Conference Call ID: 324 588 583

U.S. / Canada Replay Dial-in Number: +1 833-309-1852 International Replay Dial-in Number: +44 800 007 4044 Playback ID: 324 588 583
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, https://investors.biomarin.com/. A replay of the call will be archived on the site for one week following the call.
About BioMarin BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
Contacts:
Investors Media
Traci McCarty Marni Kottle
BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.
(415) 455-7558 (650) 374-2803

Frequently Asked Questions

When will BioMarin's Q3 2026 conference call take place?

The conference call is scheduled for November 2, 2026, at 4:30 p.m. ET.

Who will host the BioMarin conference call?

Alexander Hardy, President and CEO of BioMarin, will host the call.

How can I access the conference call?

The call can be accessed via the investor section of BioMarin's website.

Is there a replay available for the call?

Yes, a replay will be available for one week following the call.

Last updated: Oct 26, 2026